0

Yu Zhang

Heilongjiang Bayi Agricultural University, China

Title: TBA

Abstract

Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programmed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy.

Biography

Zhang Yu has completed her B.S at the age of 23 years from College of Life Science and Technology of Heilongjiang Bayi Agricultural University, China. She is currently studying for a master's degree. She is the deputy secretary of the Youth League Committee of the College of Life Science and Technology of Heilongjiang Bayi Agricultural University. She has published 29 papers (the first author has published 5 papers), 1 invention patent, and won 17 prizes in competitions.